Rationale and Study Design of the IRENE-Trial (NVALT-16): A Phase II Trial to Evaluate Iressa Rechallenge in Advanced NSCLC Patients With an Activating EGFR Mutation Who Responded to an EGFR-TKI Used As First-Line or Previous Treatment

Author:

Kuiper Justine L.,Heideman Danielle A.M.,Würdinger Tom,Grünberg Katrien,Groen Harry J.M.,Smit Egbert F.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Paclitaxel-carboplatin alone or with bevacizumab for non–small-cell lung cancer;Sandler;N Engl J Med,2006

3. Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non–small-cell lung cancer (NSCLC) patients (pts);Barlesi;J Clin Oncol,2013

4. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non–small-cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China;Wu;J Thorac Oncol,2007

5. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma;Smits;Cell Oncol (Dordr),2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3